Search Results Search Sort by RelevanceMost Recent Viewpoint Dec 2002 The Twelve Days of Christmas Audiey Kao, MD, PhD Virtual Mentor. 2002;4(12):370-371. doi: 10.1001/virtualmentor.2002.4.12.dykn1-0212. Case and Commentary Dec 2019 How Should “CRISPRed” Babies Be Monitored Over Their Life Course to Promote Health Equity? Charis Thompson, PhD Transnational monitoring efforts should focus on safety, defining standard of care, and promoting just access to innovation. AMA J Ethics. 2019;21(12):E1036-1041. doi: 10.1001/amajethics.2019.1036. Case and Commentary Jul 2019 Should Dialysis Be Stopped for an Unrepresented Patient With Metastatic Cancer? Adira Hulkower, JD, MS, Sarah Garijo-Garde, and Lauren S. Flicker, JD, MBE Legal inconsistencies and variation in end-of-life options generate disparities in care for unrepresented patients. AMA J Ethics. 2019;21(7):E575-581. doi: 10.1001/amajethics.2019.575. In the Literature Oct 2002 Should Clinician-Researchers Disclose Financial Incentives to Patients? Jeremy Spevick Virtual Mentor. 2002;4(10):299-301. doi: 10.1001/virtualmentor.2002.4.10.jdsc1-0210. Podcast Dec 2022 Author Interview: “Solidarity in Mortal Time” Dr Helen Stanton Chapple joins Ethics Talk to discuss her article: "Solidarity in Mortal Time.” Medicine and Society Dec 2022 Solidarity in Mortal Time Helen Stanton Chapple, PhD, RN, MSN, MA The concept of mortal time is useful for exploring how hospice care frameworks might help nonhospice clinicians find calm in practice. AMA J Ethics. 2022;24(12):E1149-1154. doi: 10.1001/amajethics.2022.1149. In the Literature Apr 2005 Self-Regulation and the Relationship of Physicians with the Pharmaceutical Industry Justin M. Thomas Virtual Mentor. 2005;7(4):288-293. doi: 10.1001/virtualmentor.2005.7.4.jdsc1-0504. Medical Education Aug 2006 Pharmaceutical Support of Dermatology Residency Electives: Slippery Slope or Synergy? Alfred T. Lane, MD Virtual Mentor. 2006;8(8):509-511. doi: 10.1001/virtualmentor.2006.8.8.medu1-0608. Case and Commentary Aug 2005 Finding the (Right) Time: Physician-to-Drug Rep Communication Michael E. Roloff, PhD and Rachel Malis, MA Virtual Mentor. 2005;7(8):554-558. doi: 10.1001/virtualmentor.2005.7.8.ccas5-0508. Case and Commentary Nov 2006 Distributing Drug Samples in a Free Clinic: A Personal or Policy Decision? Amanda J. Redig Virtual Mentor. 2006;8(11):729-734. doi: 10.1001/virtualmentor.2006.8.11.conl1-0611. Pagination Current page 1 Page 2 Page 3 Page 4 Next page Next › Last page Last »
Viewpoint Dec 2002 The Twelve Days of Christmas Audiey Kao, MD, PhD Virtual Mentor. 2002;4(12):370-371. doi: 10.1001/virtualmentor.2002.4.12.dykn1-0212.
Case and Commentary Dec 2019 How Should “CRISPRed” Babies Be Monitored Over Their Life Course to Promote Health Equity? Charis Thompson, PhD Transnational monitoring efforts should focus on safety, defining standard of care, and promoting just access to innovation. AMA J Ethics. 2019;21(12):E1036-1041. doi: 10.1001/amajethics.2019.1036.
Case and Commentary Jul 2019 Should Dialysis Be Stopped for an Unrepresented Patient With Metastatic Cancer? Adira Hulkower, JD, MS, Sarah Garijo-Garde, and Lauren S. Flicker, JD, MBE Legal inconsistencies and variation in end-of-life options generate disparities in care for unrepresented patients. AMA J Ethics. 2019;21(7):E575-581. doi: 10.1001/amajethics.2019.575.
In the Literature Oct 2002 Should Clinician-Researchers Disclose Financial Incentives to Patients? Jeremy Spevick Virtual Mentor. 2002;4(10):299-301. doi: 10.1001/virtualmentor.2002.4.10.jdsc1-0210.
Podcast Dec 2022 Author Interview: “Solidarity in Mortal Time” Dr Helen Stanton Chapple joins Ethics Talk to discuss her article: "Solidarity in Mortal Time.”
Medicine and Society Dec 2022 Solidarity in Mortal Time Helen Stanton Chapple, PhD, RN, MSN, MA The concept of mortal time is useful for exploring how hospice care frameworks might help nonhospice clinicians find calm in practice. AMA J Ethics. 2022;24(12):E1149-1154. doi: 10.1001/amajethics.2022.1149.
In the Literature Apr 2005 Self-Regulation and the Relationship of Physicians with the Pharmaceutical Industry Justin M. Thomas Virtual Mentor. 2005;7(4):288-293. doi: 10.1001/virtualmentor.2005.7.4.jdsc1-0504.
Medical Education Aug 2006 Pharmaceutical Support of Dermatology Residency Electives: Slippery Slope or Synergy? Alfred T. Lane, MD Virtual Mentor. 2006;8(8):509-511. doi: 10.1001/virtualmentor.2006.8.8.medu1-0608.
Case and Commentary Aug 2005 Finding the (Right) Time: Physician-to-Drug Rep Communication Michael E. Roloff, PhD and Rachel Malis, MA Virtual Mentor. 2005;7(8):554-558. doi: 10.1001/virtualmentor.2005.7.8.ccas5-0508.
Case and Commentary Nov 2006 Distributing Drug Samples in a Free Clinic: A Personal or Policy Decision? Amanda J. Redig Virtual Mentor. 2006;8(11):729-734. doi: 10.1001/virtualmentor.2006.8.11.conl1-0611.